Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
A phase 1/2 trial of Zevorcabtagene autoleucel in multiple myeloma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.
Overview
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) is a phase 1/2 interventional study registered as NCT03915184 by CARsgen Therapeutics Co., Ltd., with 105 participants planned, started 2019-09-25 and due to reach its primary completion in 2024-12-31. Interventions recorded: zevor-cel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Setting
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
Phase
Phase 1/2
Sponsor
CARsgen Therapeutics Co., Ltd.
Registry
Enrolled
105